Condition
Diabetes Mellitus, Type 2
Locations
Not recruiting
Start date
11/07/2025
Identifiers
Trial ID NN1471-5026,
NCT number NCT07068295,
Eudract number Not Available
NCT number NCT07068295,
Eudract number Not Available
Summary
This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump. The study tests how fast insulin NNC0471-0119 enters bloodstream, how long it stays there and how much it lowers blood sugar. The new insulin NNC0471-0119 will be compared to insulin aspart. The study will last for about 13-67 days (or a half to 2 months).
Trial Overview:
Treatment
DRUG: NNC0471-0119 H
DRUG: Insulin Aspart
Study type
INTERVENTIONAL
Trial duration
Jul 11 2025 - Jan 12 2026
Participants
65
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 69 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.